Latest news

• GSK seeks EU approval for Trelegy in adult asthma patients

  GSK’s respiratory business has been hit with the loss of patent protection for its COPD blockbuster Seretide/Advair (fluticasone propionate/salmeterol) – Trelegy is GSK’s answer to the increased competition

• GSK considers more divestments to help R&D push

  She said it was encouraging that in the year that generic competition really bit hard into sales of GSK’s longstanding respiratory blockbuster Advair/Seretide (fluticasone propionate/salmeterol), the group was

• Boehringer posts solid first half as business revamp beds in

  Meanwhile, the COPD category has been affected by the arrival of generics of big-selling brands like GlaxoSmithKline’s Advair (salmeterol/fluticasone propionate).

• GSK’s Advair Diskus faces first generic in US

  Teva won approval for its AirDuo product last year in the US, providing the same active ingredients as Advair but with a lower dose of salmeterol which means it is not

• Is GSK planning to exit the respiratory business?

  Much of its recent success was built on the back of combination therapies that were first introduced in the late 1980s, and culminated in its blockbuster Advair/Seretide (salmeterol/fluticasone propionate)